Newsroom
Category
December 5, 2016
More than 7,000 oncologists, cancer researchers and patient advocates will converge on San Antonio Dec. 6-10 for the 39th San Antonio Breast Cancer Symposium (SABCS) in the Henry B. Gonzalez Convention Center. Among them will be researchers and oncologists from the Cancer Therapy & Research Center of the UT Health Science Center San Antonio, which founded the conference in 1978.
December 5, 2016
More than 7,000 oncologists, cancer researchers and patient advocates will converge on San Antonio Dec. 6-10 for the 39th San Antonio Breast Cancer Symposium (SABCS) in the Henry B. Gonzalez Convention Center.
December 1, 2016
Adding everolimus to fulvestrant in postmenopausal women with hormone receptor (HR)-positive/HER2-negative, aromatase inhibitor (AI)-resistant metastatic breast cancer improved progression-free survival (PFS) to 10.4 months, compared with 5.1 months for fulvestrant alone, in the randomized, double-blind, Phase II PrECOG 0102 trial. Read the full story at Clinical Oncology News
December 1, 2016
Adding the PARP inhibitor veliparib to carboplatin and paclitaxel chemotherapy significantly increased response rates among women with BRCA1 or BRCA2 mutations and locally recurrent or metastatic breast cancer, according to a randomized phase II trial. Read the full story at Cancer Network
December 1, 2016
Accurate assessment of the extent of disease, or Stage, at the time of diagnosis, is one determinant of prognosis or risk of future recurrence of the cancer, and also determines ideal initial treatment. Read the full story at KMIZ 17
November 22, 2016
The San Antonio Cancer Foundation is pledging $17 million to support the new affiliation between the University of Texas Health Science Center’s Cancer Therapy and Research Center and M-D Anderson Cancer Center in Houston.
